{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T15:36:49Z","timestamp":1787067409660,"version":"build-2736575974"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2023,8,19]],"date-time":"2023-08-19T00:00:00Z","timestamp":1692403200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,7,3]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tacrolimus (TAC), a calcineurin inhibitor, is used for remission induction therapy in patients with moderate to severe ulcerative colitis (UC), with short-term efficacy and related predictive factors shown in previous cohort studies. However, most studies reported data for only a limited number of patients enrolled from a single center. We performed a large multicenter retrospective cohort study to identify factors related to prediction of clinical remission in UC patients treated with oral TAC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The medical records of patients with moderate to severe UC treated with oral TAC as induction therapy at 7 institutions between April 2009 and March 2017 were retrospectively reviewed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 216 patients who received TAC for induction were analyzed, of whom 123 (56.9%) showed clinical remission at week 12. Logistic regression analysis indicated that previous or current use of antitumor necrosis factor (TNF)-\u03b1 antibodies (odds ratio [OR], 0.259; P = .006), and concomitant treatment with 5-aminosalicylate (5-ASA) at the baseline (OR, 0.268; P = .005) were independent predictive factors correlated with failure of clinical remission, whereas higher levels of C-reactive protein (OR, 1.124; P = .014) predicted achievement of clinical remission.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Results of this multicenter study clearly indicate the efficacy of TAC induction therapy for patients with moderate to severe UC. Notably, previous or current use of anti-TNF-\u03b1 antibodies was associated with poor achievement of clinical remission by week 12.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ibd\/izad150","type":"journal-article","created":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T16:39:03Z","timestamp":1689266343000},"page":"1087-1093","source":"Crossref","is-referenced-by-count":4,"title":["Predictive Factors for Efficacy of Oral Tacrolimus Induction Therapy in Moderate to Severe Ulcerative Colitis Patients: Large Multicenter Retrospective Cohort Study"],"prefix":"10.1093","volume":"30","author":[{"given":"Naoki","family":"Oshima","sequence":"first","affiliation":[{"name":"Inflammatory Bowel Disease Center, Shimane University Hospital , 89-1, Enya-cho, Izumo, Shimane 693-8501 , Japan"},{"name":"Department of Internal Medicine II, Shimane University Faculty of Medicine , 89-1, Enya-cho, Izumo, Shimane 693-8501 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakiko","family":"Hiraoka","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryohei","family":"Hayashi","sequence":"additional","affiliation":[{"name":"Department of Endoscopy, Hiroshima University Hospital , Hiroshima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sakuma","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kagawa Prefectural Central Hospital , Kagawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Ishii","sequence":"additional","affiliation":[{"name":"General Internal Medicine 2, General Medical Center, Kawasaki Medical School , Okayama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Hashimoto","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine , Yamaguchi , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuo","family":"Yashima","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Nephrology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University , Tottori , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoko","family":"Igawa","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Inokuchi","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences , Okayama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Ueno","sequence":"additional","affiliation":[{"name":"Department of Endoscopy, Hiroshima University Hospital , Hiroshima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoki","family":"Inaba","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology, Kagawa Prefectural Central Hospital , Kagawa , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Kawasaki Medical School , Okayama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5815-0066","authenticated-orcid":false,"given":"Kousaku","family":"Kawashima","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Shimane University Hospital , 89-1, Enya-cho, Izumo, Shimane 693-8501 , Japan"},{"name":"Department of Internal Medicine II, Shimane University Faculty of Medicine , 89-1, Enya-cho, Izumo, Shimane 693-8501 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Takami","sequence":"additional","affiliation":[{"name":"Department of Gastroenterology and Hepatology, Yamaguchi University Graduate School of Medicine , Yamaguchi , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hajime","family":"Isomoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Nephrology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University , Tottori , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Shiotani","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Kawasaki Medical School , Okayama , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Endoscopy, Hiroshima University Hospital , Hiroshima , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8228-1912","authenticated-orcid":false,"given":"Shunji","family":"Ishihara","sequence":"additional","affiliation":[{"name":"Inflammatory Bowel Disease Center, Shimane University Hospital , 89-1, Enya-cho, Izumo, Shimane 693-8501 , Japan"},{"name":"Department of Internal Medicine II, Shimane University Faculty of Medicine , 89-1, Enya-cho, Izumo, Shimane 693-8501 , Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,8,19]]},"reference":[{"issue":"6","key":"2024070305512539900_CIT0001","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMra020831","article-title":"Inflammatory bowel disease","volume":"347","author":"Podolsky","year":"2002","journal-title":"N Engl J Med."},{"issue":"10080","key":"2024070305512539900_CIT0002","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1016\/S0140-6736(16)32126-2","article-title":"Ulcerative colitis","volume":"389","author":"Ungaro","year":"2017","journal-title":"Lancet"},{"issue":"18","key":"2024070305512539900_CIT0003","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMra1102942","article-title":"Ulcerative colitis","volume":"365","author":"Danese","year":"2011","journal-title":"N Engl J Med."},{"issue":"1","key":"2024070305512539900_CIT0004","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.cgh.2006.09.033","article-title":"Response to corticosteroids in severe ulcerative colitis: a systematic review of the literature and a meta-regression","volume":"5","author":"Turner","year":"2007","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"9","key":"2024070305512539900_CIT0005","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1093\/ecco-jcc\/jjaa053","article-title":"The historical role and contemporary use of corticosteroids in inflammatory bowel disease","volume":"14","author":"Dorrington","year":"2020","journal-title":"J Crohns Colitis"},{"issue":"10","key":"2024070305512539900_CIT0006","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1111\/j.1572-0241.1998.539_g.x","article-title":"Steroid-unresponsive acute attacks of inflammatory bowel disease: immunomodulation by tacrolimus (FK506)","volume":"93","author":"Fellermann","year":"1998","journal-title":"Am J Gastroenterol."},{"issue":"2","key":"2024070305512539900_CIT0007","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00535-010-0352-z","article-title":"The use of traditional and newer calcineurin inhibitors in inflammatory bowel disease","volume":"46","author":"Naganuma","year":"2011","journal-title":"J Gastroenterol."},{"issue":"3","key":"2024070305512539900_CIT0008","doi-asserted-by":"crossref","first-page":"219","DOI":"10.5217\/ir.2015.13.3.219","article-title":"Tacrolimus for the treatment of ulcerative colitis","volume":"13","author":"Matsuoka","year":"2015","journal-title":"Intest Res"},{"issue":"1","key":"2024070305512539900_CIT0009","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1093\/ibd\/izz068","article-title":"Tacrolimus therapy in steroid-refractory ulcerative colitis: a review","volume":"26","author":"Wu","year":"2020","journal-title":"Inflamm Bowel Dis."},{"issue":"8670","key":"2024070305512539900_CIT0010","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1016\/S0140-6736(89)91014-3","article-title":"FK 506 for liver, kidney, and pancreas transplantation","volume":"2","author":"Starzl","year":"1989","journal-title":"Lancet."},{"issue":"5","key":"2024070305512539900_CIT0011","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ibd.21853","article-title":"Double-blind, placebo-controlled trial of oral tacrolimus (FK506) in the management of hospitalized patients with steroid-refractory ulcerative colitis","volume":"18","author":"Ogata","year":"2012","journal-title":"Inflamm Bowel Dis."},{"issue":"4","key":"2024070305512539900_CIT0012","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/ecco-jcc\/jjv221","article-title":"Efficacy and safety of tacrolimus therapy for active ulcerative colitis; a systematic review and meta-analysis","volume":"10","author":"Komaki","year":"2016","journal-title":"J Crohns Colitis"},{"issue":"1","key":"2024070305512539900_CIT0013","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO guidelines on therapeutics in ulcerative colitis: medical treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J Crohns Colitis"},{"issue":"5","key":"2024070305512539900_CIT0014","doi-asserted-by":"crossref","first-page":"1450","DOI":"10.1053\/j.gastro.2020.01.006","article-title":"AGA institute clinical guidelines committee. AGA clinical practice guidelines on the management of moderate to severe ulcerative colitis","volume":"158","author":"Feuerstein","year":"2020","journal-title":"Gastroenterology."},{"issue":"6","key":"2024070305512539900_CIT0015","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s00535-021-01784-1","article-title":"Evidence-based clinical practice guidelines for inflammatory bowel disease 2020","volume":"56","author":"Nakase","year":"2021","journal-title":"J Gastroenterol."},{"issue":"26","key":"2024070305512539900_CIT0016","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1056\/NEJM199406303302601","article-title":"Cyclosporine in severe ulcerative colitis refractory to steroid therapy","volume":"330","author":"Lichtiger","year":"1994","journal-title":"N Engl J Med."},{"issue":"1","key":"2024070305512539900_CIT0017","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1111\/apt.12118","article-title":"Short-term efficacy of tacrolimus in steroid-refractory ulcerative colitis - experience in 130 patients","volume":"37","author":"Schmidt","year":"2013","journal-title":"Aliment Pharmacol Ther."},{"issue":"3","key":"2024070305512539900_CIT0018","doi-asserted-by":"crossref","first-page":"e0213505","DOI":"10.1371\/journal.pone.0213505","article-title":"Pretreatment neutrophil-to-lymphocyte ratio predicts clinical relapse of ulcerative colitis after tacrolimus induction","volume":"14","author":"Nishida","year":"2019","journal-title":"PLoS One."},{"issue":"1","key":"2024070305512539900_CIT0019","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.cgh.2018.05.026","article-title":"Rapid response to vedolizumab therapy in biologic-naive patients with inflammatory bowel diseases","volume":"17","author":"Feagan","year":"2019","journal-title":"Clin Gastroenterol Hepatol."},{"issue":"11","key":"2024070305512539900_CIT0020","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/apt.15717","article-title":"Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study","volume":"51","author":"Amiot","year":"2020","journal-title":"Aliment Pharmacol Ther."},{"issue":"6","key":"2024070305512539900_CIT0021","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1111\/apt.13531","article-title":"Tacrolimus vs. anti-tumour necrosis factor agents for moderately to severely active ulcerative colitis: a retrospective observational study","volume":"43","author":"Yamamoto","year":"2016","journal-title":"Aliment Pharmacol Ther."},{"issue":"1","key":"2024070305512539900_CIT0022","doi-asserted-by":"crossref","first-page":"12546","DOI":"10.1038\/s41598-020-68828-z","article-title":"Comparative efficacy of antitumor necrosis factor agents and tacrolimus in naive steroid-refractory ulcerative colitis patients","volume":"10","author":"Kitayama","year":"2020","journal-title":"Sci Rep."},{"issue":"1","key":"2024070305512539900_CIT0023","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/jgh.15138","article-title":"Multicenter survey on mesalamine intolerance in patients with ulcerative colitis","volume":"36","author":"Hiraoka","year":"2021","journal-title":"J Gastroenterol Hepatol."},{"issue":"12","key":"2024070305512539900_CIT0024","doi-asserted-by":"crossref","first-page":"e609","DOI":"10.1016\/j.crohns.2013.04.018","article-title":"Mucosal healing with oral tacrolimus is associated with favorable medium- and long-term prognosis in steroid-refractory\/dependent ulcerative colitis patients","volume":"7","author":"Miyoshi","year":"2013","journal-title":"J Crohns Colitis"},{"issue":"5","key":"2024070305512539900_CIT0025","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1016\/j.dld.2015.01.149","article-title":"Tacrolimus for remission induction in ulcerative colitis: Mayo endoscopic subscore 0 and 1 predict long-term prognosis","volume":"47","author":"Ikeya","year":"2015","journal-title":"Dig Liver Dis."}],"container-title":["Inflammatory Bowel Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ibdjournal\/advance-article-pdf\/doi\/10.1093\/ibd\/izad150\/51175377\/izad150.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/7\/1087\/58282324\/izad150.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article-pdf\/30\/7\/1087\/58282324\/izad150.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T01:52:24Z","timestamp":1719971544000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ibdjournal\/article\/30\/7\/1087\/7246447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,19]]},"references-count":25,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,8,19]]},"published-print":{"date-parts":[[2024,7,3]]}},"URL":"https:\/\/doi.org\/10.1093\/ibd\/izad150","relation":{},"ISSN":["1078-0998","1536-4844"],"issn-type":[{"value":"1078-0998","type":"print"},{"value":"1536-4844","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,7,1]]},"published":{"date-parts":[[2023,8,19]]}}}